Clinical Trials

Several clinical trials evaluate the diagnostic and prognostic utility of mebrofenin-based imaging across hepatic conditions such as liver dysfunction, regeneration, hepatocellular carcinoma, fibrosis, cirrhosis, and non-alcoholic steatohepatitis. Encompassing Phase 1 and observational designs, these studies are sponsored by academic centers including the McGill University Health Centre, Vilnius University, and the University of North Carolina at Chapel Hill. Spanning completed, actively recruiting, terminated, and withdrawn statuses, these protocols quantify hepatocyte function and hepatobiliary clearance to optimize risk stratification and patient management.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05280990 WITHDRAWN
Liver Failure as A Complication of Care; 30-day Mortality
Boris Gala Lopez
2023-01-15
NCT06126419 Recruiting
Liver Dysfunction|Liver Metastasis Colon Cancer|Liver Regeneration
McGill University Health Centre/Research Institute of the McGill University Health Centre
2023-11-08 Not Applicable
NCT02235233 COMPLETED
Non-alcoholic Steatohepatitis
University of North Carolina, Chapel Hill
2015-04 PHASE1
NCT00767468 Terminated
Liver Cancer
UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)
2008-10 Phase 1

(data from https://clinicaltrials.gov, updated on 2024-02-07)

Check the Mebrofenin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As an iminodiacetic acid derivative radiolabeled with technetium-99m, mebrofenin selectively binds organic anion transporting polypeptides on hepatocyte membranes, facilitating rapid intracellular uptake and subsequent excretion into biliary canaliculi via multidrug resistance-associated proteins without undergoing metabolic conversion. This active hepatobiliary transport mechanism enables real-time scintigraphic measurement of functional liver mass and bile flow dynamics, providing critical diagnostic value in assessing hepatic dysfunction, liver cirrhosis, and post-surgical liver regeneration.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.